KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Net Margin: 2009-2025

Historic Net Margin for Rigel Pharmaceuticals (RIGL) over the last 12 years, with Sep 2025 value amounting to 40.17%.

  • Rigel Pharmaceuticals' Net Margin rose 1771.00% to 40.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.15%, marking a year-over-year increase of 3768.00%. This contributed to the annual value of 9.74% for FY2024, which is 3121.00% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Net Margin of 40.17% as of Q3 2025, which was down 31.49% from 58.63% recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Net Margin ranged from a high of 58.63% in Q2 2025 and a low of -164.00% during Q1 2022.
  • For the 3-year period, Rigel Pharmaceuticals' Net Margin averaged around 3.83%, with its median value being 2.06% (2023).
  • Within the past 5 years, the most significant YoY rise in Rigel Pharmaceuticals' Net Margin was 11,350bps (2022), while the steepest drop was 21,275bps (2022).
  • Rigel Pharmaceuticals' Net Margin (Quarterly) stood at -110.76% in 2021, then soared by 11,350bps to 2.73% in 2022, then tumbled by 67bps to 2.06% in 2023, then skyrocketed by 2,281bps to 24.87% in 2024, then soared by 1,771bps to 40.17% in 2025.
  • Its Net Margin was 40.17% in Q3 2025, compared to 58.63% in Q2 2025 and 21.40% in Q1 2025.